Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach

PLoS One. 2017 Jan 25;12(1):e0170846. doi: 10.1371/journal.pone.0170846. eCollection 2017.

Abstract

PARP-1 inhibition has been studied over the last decades for the treatment of various diseases. Despite the fact that several molecules act as PARP-1 inhibitors, a reduced number of compounds are used in clinical practice. To identify new compounds with a discriminatory PARP-1 inhibitory function, explicit-solvent molecular dynamics simulations using different inhibitors bound to the PARP-1 catalytic domain were performed. The representative structures obtained were used to generate structure-based pharmacophores, taking into account the dynamic features of receptor-ligand interactions. Thereafter, a virtual screening of compound databases using the pharmacophore models obtained was performed and the hits retrieved were subjected to molecular docking-based scoring. The drug-like molecules featuring the best ranking were evaluated for their PARP-1 inhibitory activity and IC50 values were calculated for the top scoring docked compounds. Altogether, three new PARP-1 inhibitor chemotypes were identified.

MeSH terms

  • Catalytic Domain
  • Databases, Pharmaceutical
  • Humans
  • Ligands
  • Models, Molecular*
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Poly (ADP-Ribose) Polymerase-1 / antagonists & inhibitors*
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Ligands
  • Poly (ADP-Ribose) Polymerase-1

Grants and funding

JARS thanks Universidade de Coimbra for financial support. SJB thanks Fundação para a Ciência e a Tecnologia for financial support (SFRH/BD/80975/2011). GC acknowledges funding from AIRC through project IG 15420. The authors gratefully acknowledge UC-NMR facility, which is supported by FEDER – European Regional Development Fund through the COMPETE Programme (Operational Programme for Competitiveness), as well as by National Funds through FCT – Fundação para a Ciência e a Tecnologia (Portuguese Foundation for Science and Technology) through grants REEQ/481/QUI/2006, RECI/QEQ-QFI/0168/2012, CENTRO-07-CT62-FEDER-002012, and Rede Nacional de Ressonância Magnética Nuclear (RNRMN), for NMR data. We are also grateful to Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute for kindly providing the compounds screened in this study.